Tag:
ALK
Latest Headlines
Latest Headlines
Merck plans NDA on promising Phase III data for allergy pill
Merck ( $MRK ) has taken a step closer to an NDA for its new allergy pill.
Merck scores promising pivotal data on allergy treatment
Denmark's ALK-Abello is spreading the word that its Big Pharma partner, Merck, has nailed down promising data in two late-stage studies of its experimental ragweed therapy, setting the stage for a
